|
Jul 18
|
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
|
|
Jul 17
|
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
|
|
Jul 17
|
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
|
|
Jul 16
|
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
|
|
May 28
|
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
|
|
Feb 23
|
Akero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025
|
|
Feb 19
|
Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025
|
|
Sep 30
|
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
|
|
Sep 9
|
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
|
|
Sep 5
|
Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now
|
|
Aug 28
|
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Jul 16
|
Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
|
|
Jun 11
|
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
|
|
May 13
|
Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...
|
|
May 10
|
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 8
|
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
|
|
Apr 30
|
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
|
|
Mar 20
|
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
|
|
Mar 18
|
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
|
|
Mar 15
|
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
|